|
Feature
|
No. of patients [cases (%)]
|
|---|
|
Sex
|
|
Male
|
580 (77.4)
|
|
Female
|
169 (22.6)
|
|
WHO pathology
|
|
Type I
|
5 (0.7)
|
|
Type II/III
|
744 (99.3)
|
|
Clinical stagea
|
|
I–II
|
257 (34.3)
|
|
III–IV
|
492 (65.7)
|
|
T stagea
|
|
T1
|
177 (23.6)
|
|
T2
|
140 (18.7)
|
|
T3
|
264 (35.2)
|
|
T4
|
168 (22.4)
|
|
N stagea
|
|
N0
|
184 (24.6)
|
|
N1
|
409 (54.6)
|
|
N2
|
106 (14.2)
|
|
N3
|
50 (6.7)
|
|
Chemotherapy
|
|
No chemotherapy
|
214 (28.6)
|
|
Concurrent
|
243(32.5)
|
|
Induction + concurrent
|
246 (32.8)
|
|
Concurrent + adjuvant
|
46 (6.1)
|
-
WHO World Health Organization
-
aAccording to the 7th edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system
